www.varchev.com

This robot is learning how to print a human organ

Rating:

12345
Loading...

Kentucky-based software company Advanced Solutions has developed what it calls the world's first 3D human tissue printer.

Called the BioAssemblyBot, the machine is the second generation of 3D printers focused on producing biomedical materials intended to revolutionizing healthcare.

The goal is to 3D print human organs, Advanced Solutions president and CEO Michael Golway told CNBC on Friday.

The BioAssemblyBot uses a touch screen and a laser sensor to tell the robot arm and nozzle where to move and what to do next, operating on software called the Tissue Structure Informational Modeling. TISM essentially allows users to design and visualize the tissue structure before it's replicated by the BioAssemblyBot.

robot

"The tools that we've invented, like the BioAssemblyBot, are enabling our scientists and our customers to advance the biology in ways that have never been possible before, so that's very exciting," said Golway.

The most challenging aspect of the process is bioink, the material used in 3D bioprinting. Bioink must satisfy mechanical needs of the printing process while containing the elements needed to make the tissue come to life.

Golway admits his firm needs to "fail faster" in order to see accelerated progress, and acknowledged significant effort, discovery and investment are still needed before an actual organ can be printed for human use, he said.

Advanced Solutions and its customers are also using the technology to create mimics for lungs, hearts, kidneys, pancreases, bones and even human skin.

While bioprinting could solve the problem of who gets to the top of the transplant list, printing human organs creates legal and ethical problems.

Source: Bloomberg Pro Terminal

Jr Trader Z Karadzhova

 


 Varchev Traders

Read more:

RECCOMEND WAS THIS POST USEFUL FOR YOU?
If you think, we can improve that section,
please comment. Your oppinion is imortant for us.
WARNING: Any news, opinions, research, data or other information contained within this website is provided as general market commentary and does not constitute investment or trading advice. Varchev Finance Ltd. expressly disclaims any liability for any lost principal or profits which may arise directly or indirectly from the use of or reliance on such information. Varchev Finance Ltd. may provide information, quotes, references and links to or from other sites and blogs and other sources of economic and market information as an educational service to its clients and prospects and does not endorse the opinions or recommendations of the sites, blogs or other sources of information.
Varchev Finance

London


25 Canada Square, Level 33, office 50, Canary Wharf London, E14 5LQ +44 20 3608 6256

Universal numbers

World Financial Markets - 0700 17 600    Varchev Exchange - 0700 115 44

Varchev Finance Ltd is registered in the FCA (FINANCIAL CONDUCT AUTHORITY) with a passport in the United Kingdom: FCA, United Kingdom - registration number: 494 045, which allows provision of financial services in the United Kingdom.

Varchev Finance Ltd strictly comply with the statutes of the European directive MiFID (Markets in Financial Instruments). targeting increased efficiency, transparency and uniformity of financial instruments.
Varchev Finance Ltd is authorized and regulated by the Financial Supervision Commission - Sofia, Bulgaria: License number RG-03-02-05 / 15.03.2006

The information on this site is not intended for distribution or use by any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.


Disclaimer:

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 63,41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.

chat with dealer
chat with dealer
Cookies policy